Icell Gene Therapeutics LLC

Rb Health (us) LLC

Apvlab, LLC

Microsoft Technology Licensing, LLC

Rubbo International, Inc.

Kevin Chen

Yupo Ma

Kevin Pinz

Xun Jiang

Masayuki Wada

Matthew James Kaser

Raghu Cavatur

Hongchun Qiu

Ernest Joseph Woodhouse

Josef Borovicka

Elliot Wilkinson

David Michael Lane

Brian David Bitz

Anthony George Picardo

Anthony Ernest Hillyerd

Colin Michael Ravenscroft

Jason Dale Brown

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of guaifenesin, naproxen and at least one further active which is selected to be an antitussive, a decongestant or an antihistamine.

Pharmaceutical formulation

The present disclosure provides chimeric antigen receptors, compostions, and methods thereof. In one embodiment the present disclosure provides a method of treating autoimmune diseases, asthma, and preventing or mediating organ rejection in a subject.

Chimeric antigen receptors (CARs), compositions and methods thereof

A formulation for oral administration comprises an expectorant, an analgesic, and at least one additional active ingredient having a modified release providing a therapeutic effect for each of the active ingredients for up to 12 hours.

In one embodiment, the present disclosure provides an engineered cell having a first chimeric antigen receptor polypeptide including a first antigen recognition domain, a first signal peptide, a first hinge region, a first transmembrane domain, a first costimulatory domain, and a first signaling domain; and a second chimeric antigen receptor polypeptide including a second antigen recognition domain, a second signal peptide, a second hinge region, a second transmembrane domain, a second co-stimulatory domain, and a second signaling domain; wherein the first antigen recognition domain is different than the second antigen recognition domain.

Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof

The present invention relates to compositions and methods relating to chimeric antigen receptor (CAR) polypeptides and methods relating thereto. In one embodiment, the present invention relates to engineered cells having chimeric antigen receptor polypeptides directed to at least two targets. In another embodiment, the present invention relates to engineered cells having chimeric antigen receptor polypeptides and an enhancer moiety.

Chimeric antigen receptors (CARs), compositions and methods of use thereof

The description relates to devices and device adjustment. One example can include a first portion that defines a cam pivot. The example can also include a height adjuster comprising a wedge and a positioning loop positioned over the cam pivot, such that rotation of a cam on the cam pivot to contact one cam follower of the positioning loop that moves the wedge toward another component or to contact an opposite cam follower of the positioning loop that moves the wedge away from the another component.

Device cam-controlled adjustment

A package system is provided. The package system comprises a carton having at least a first carton panel including a first tab having a first tab edge defined by internal walls of the first panel, a second carton panel opposing the first panel, and a third carton panel between the first carton panel and the second carton panel, the carton having a carton length that is defined as a first distance parallel to the third carton panel between the first carton panel and the second carton panel; and a drawer configured to slide into and out of an interior of the carton, the drawer having at least a first drawer panel opposing the first carton panel, a second drawer panel opposing the second carton panel, and a third drawer panel opposing the third carton panel, the third drawer panel adjoined between the first drawer panel and the second drawer panel.

Package system

The present disclosure relates to compositions and methods relating to chimeric antigen receptor (CAR) polypeptides and methods relating thereto. In one embodiment, the present disclosure relates to engineered cells having chimeric antigen receptor polypeptides directed to at least two targets. In another embodiment, the present disclosure relates to engineered cells having chimeric antigen receptor polypeptides and an enhancer moiety.

Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof

A dual air flow rebuildable dripping atomizer for use with electronic cigarettes which uses a sleeve lock that allows the user to adjust and direct the air flow is provided. The adjustable air flow sleeve also allows the sleeve to be locked in place preventing the e-liquid from leaking out. Rotating the adjustable air flow sleeve in a clockwise or counter-clockwise direction allows not only the direction of the air flow to be determined but how much air enters an inner air chamber of the atomizer. As a result, a user can determine, for example, the size of the vapor cloud and the intensity of the flavor. Additionally, the adjustable air flow sleeve may be adjusted to block air holes located on an inner edge surface of the adjustable air flow sleeve preventing the e-liquid from leaking.

Dual air flow rebuildable dripping atomizer with an adjustable air flow sleeve for an electronic cigarette

The present disclosure provides chimeric antigen receptor polypeptides having antigen recognition domains for CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens, and polynucleotides encoding for the same. The present disclosure also provides for engineered cells expressing the polynucleotide or polypeptides. In some embodiments, the disclosure provides methods for treating diseases associated with CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens.

Growing community of inventors

Stony Brook, NY, United States of America

Kevin Chen